Format
Sort by

Send to

Choose Destination

Links from Books

Items: 14

1.

On the Assessment of Monte Carlo Error in Simulation-Based Statistical Analyses.

Koehler E, Brown E, Haneuse SJ.

Am Stat. 2009 May 1;63(2):155-162.

2.

Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.

Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, Daniell G, Heesakkers J, Haag-Molkenteller C.

Eur Urol. 2011 Oct;60(4):742-50. doi: 10.1016/j.eururo.2011.07.002.

PMID:
21798658
3.

Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial.

Herschorn S, Gajewski J, Ethans K, Corcos J, Carlson K, Bailly G, Bard R, Valiquette L, Baverstock R, Carr L, Radomski S.

J Urol. 2011 Jun;185(6):2229-35. doi: 10.1016/j.juro.2011.02.004.

PMID:
21497851
4.

Catalogue of EQ-5D scores for the United Kingdom.

Sullivan PW, Slejko JF, Sculpher MJ, Ghushchyan V.

Med Decis Making. 2011 Nov-Dec;31(6):800-4. doi: 10.1177/0272989X11401031.

PMID:
21422468
5.

Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity.

Padmanabhan P, Scarpero HM, Milam DF, Dmochowski RR, Penson DF.

World J Urol. 2011 Feb;29(1):51-7. doi: 10.1007/s00345-010-0618-3.

PMID:
21110030
6.

Exploring the impact of changes in neurogenic urinary incontinence frequency and condition-specific quality of life on preference-based outcomes.

Hollingworth W, Campbell JD, Kowalski J, Ravelo A, Girod I, Briggs A, Sullivan SD.

Qual Life Res. 2010 Apr;19(3):323-31. doi: 10.1007/s11136-010-9590-z.

PMID:
20094804
7.

Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction.

Pannek J, Göcking K, Bersch U.

BJU Int. 2009 Nov;104(9):1246-50. doi: 10.1111/j.1464-410X.2009.08600.x.

8.

Comparison of extraperitoneal and intraperitoneal augmentation enterocystoplasty for neurogenic bladder in spinal cord injury patients.

Reyblat P, Chan KG, Josephson DY, Stein JP, Freeman JA, Grossfeld GD, Esrig D, Ginsberg DA.

World J Urol. 2009 Feb;27(1):63-8. doi: 10.1007/s00345-008-0351-3.

PMID:
19020878
9.

Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity.

Apostolidis A, Jacques TS, Freeman A, Kalsi V, Popat R, Gonzales G, Datta SN, Ghazi-Noori S, Elneil S, Dasgupta P, Fowler CJ.

Eur Urol. 2008 Jun;53(6):1245-53. doi: 10.1016/j.eururo.2008.02.037.

PMID:
18343564
10.

Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections.

Gamé X, Castel-Lacanal E, Bentaleb Y, Thiry-Escudié I, De Boissezon X, Malavaud B, Marque P, Rischmann P.

Eur Urol. 2008 Mar;53(3):613-8.

PMID:
17804150
11.
12.

What is the need for additional bladder surgery after bladder augmentation in childhood?

Metcalfe PD, Cain MP, Kaefer M, Gilley DA, Meldrum KK, Misseri R, King SJ, Casale AJ, Rink RC.

J Urol. 2006 Oct;176(4 Pt 2):1801-5; discussion 1805.

PMID:
16945653
13.

Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study.

Schurch B, de Sèze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, Plante P, Perrouin-Verbe B, Kumar C, Fraczek S, Brin MF; Botox Detrusor Hyperreflexia Study Team..

J Urol. 2005 Jul;174(1):196-200.

PMID:
15947626
14.

Long-term survival in spinal cord injury: a fifty year investigation.

Frankel HL, Coll JR, Charlifue SW, Whiteneck GG, Gardner BP, Jamous MA, Krishnan KR, Nuseibeh I, Savic G, Sett P.

Spinal Cord. 1998 Apr;36(4):266-74.

PMID:
9589527
Items per page

Supplemental Content

Support Center